Healthcare – Page 30 – The Media Pub News ™

Merck and Hanmi Pharmaceutical enter into licensing agreement to develop Efinopegdutide, an investigational once-weekly therapy for nonalcoholic steatohepatitis (NASH)

August 04, 2020

KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Hanmi Pharmaceutical today announced that the companies have entered into an exclusive licensing agreement for the development, manufacture and commercialization of efinopegdutide (formerly HM12525A), Hanmi’s investigational

Business, Healthcare

Eagle Pharmaceuticals to discuss second quarter 2020 financial results on August 10, 2020

August 04, 2020

WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 second quarter financial results on Monday, August 10, 2020, before the market opens. Scott Tarriff, Chief Executive Officer, and Pete Meyers,

Business, Healthcare

Teva announces new strategic focus in the Japanese market

July 30, 2020

Japan Business Venture shifts focus to specialty assets and a portfolio of select generics that meet patients’ medical needs Remains positioned to address unmet patient needs in core therapeutic areas Will divest majority of current non-differentiated generics portfolio, as well as local

Business, Healthcare

Bristol Myers Squibb and bluebird bio announce submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for adults with relapsed and refractory multiple myeloma

July 30, 2020

BLA submission based on results from pivotal Phase 2 KarMMa study evaluating ide-cel in heavily pre-treated patient population Companies are committed to working with the FDA to rapidly advance ide-cel through the regulatory review process PRINCETON, N.J., & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$BLUE #BMS—Bristol

Business, Healthcare

Daiichi Sankyo and AstraZeneca enter new global development and commercialization collaboration for Daiichi Sankyo’s ADC DS-1062

July 27, 2020

Agreement represents second collaboration between Daiichi Sankyo and AstraZeneca for a Daiichi Sankyo DXd antibody drug conjugate (ADC) AstraZeneca to pay Daiichi Sankyo up to $6 billion in total consideration, including a $1 billion upfront payment and up to an additional $5

Business, Healthcare

LabVantage COVID-19 LIMS solution implemented for onsite workplace health and safety

July 22, 2020

—Leading Consumer Goods Company Offers Employee Health Testing at In-House Test Centers— SOMERSET, N.J.–(BUSINESS WIRE)–#COVID–LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services including purpose-built LIMS solutions that allow labs to go live faster and at a lower total

Business, Healthcare

Bayer continues to earn top marks in 2020 Disability Equality Index

July 20, 2020

Company earns score of 90 and recognized as a Best Place to Work for Disability Inclusion WHIPPANY, N.J.–(BUSINESS WIRE)–For the second consecutive year, Bayer U.S. was recognized as a Best Place to Work for Disability Inclusion, earning a score of 90 in

Healthcare

European Medicines Agency validates Bristol Myers Squibb’s application for CAR T Cell Therapy Lisocabtagene Maraleucel (liso-cel)

July 17, 2020

MAA is for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and follicular lymphoma grade 3B Application based on positive results from TRANSCEND NHL 001 study and additional TRANSCEND WORLD 001 study PRINCETON, N.J.–(BUSINESS

Business, Healthcare

Humanigen expands partnership with Catalent biologics to manufacture investigational COVID-19 therapeutic candidate lenzilumab

July 16, 2020

Humanigen’s investigational monoclonal antibody, lenzilumab, was developed using Catalent’s proprietary GPEx® cell line development technology Expanded partnership established product supply for lenzilumab, an investigational Phase 3 product for COVID-19 Catalent’s OneBio® integrated biologics suite expected to accelerate development, manufacturing and supply of